BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
ARA-290, foto del prodotto
Healing

ARA-290

Healing

  • Spedito dalla Germania

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

In sintesi

ARA-290 in cifre

I dati chiave dalla nostra enciclopedia.

Voce completa dell'enciclopedia
Class
EPO-derived peptidenon-hematopoietic
Half-life
short
Use
Subcutaneousin mg
Sizes
10 to 16 mg2 sizes in the shop

Non esiste ancora un'analisi di laboratorio per ARA-290. Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio

Conoscenze

Tutto su ARA-290

Utili da avere

Cosa ti serve insieme

L'acqua batteriostatica viene aggiunta automaticamente al carrello. Siringhe e tamponi con un clic.

Siringhe da insulina

10 pz · 5.50 €

Tamponi imbevuti di alcol

50 pz · 10 €

Quanta acqua?

Unità sulla siringa per la misura del tuo flaconcino.

Apri il calcolatore →

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

What is ARA-290?

A small peptide with the drug name cibinetide, designed from the structure of erythropoietin. Unlike EPO it is meant not to make the body form red blood cells. It acts through the innate repair receptor, a complex of the EPO receptor and CD131.

What do the sarcoidosis studies show?

In the first pilot study with 22 participants the symptom score fell by 11.5 points after 4 weeks versus 2.9 with placebo. A second study with daily dosing under the skin for 28 days found fewer symptoms, more nerve fibres in the cornea and a longer walking distance. In the phase 2b trial with 64 participants only the middle study dose was significant.

What about type 2 diabetes?

In a phase 2 trial with daily dosing under the skin for 28 days long-term blood sugar and blood lipids improved over 56 days and so did nerve pain symptoms. In participants with clearly reduced corneal nerve fibre density this density increased, with placebo it did not.

Does ARA-290 help with eye diseases?

In diabetic macular oedema a small study with 9 participants showed no improvement in visual acuity or retinal thickness after 12 weeks. Only the visual function questionnaire came out slightly better. The trial ended early because the study drug expired.

Does ARA-290 affect mood?

In a study with 36 healthy people the brain responded more weakly to happy faces one week after dosing and attention to positive pictures increased. ARA-290 had no effect on mood or emotional state. A clear antidepressant-like profile did not emerge.

Which side effects are known?

No safety concerns appeared in the studies. In diabetic macular oedema there were no serious side effects and no antibodies against the compound after 12 weeks. The abstracts give no percentages for individual side effects.

Correlati

Prodotti correlati